GH
Guardant Health, Inc. · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 45.42K | $7.92M | n/a | n/a |
| Q2 2026 | 137 | +11 | 93.62M | $13.95B | +17 | −7 |
| Q1 2026 | 130 | -8 | 97.95M | $8.77B | +5 | −14 |
| Q4 2025 | 137 | +1 | 99.79M | $9.86B | +2 | n/a |
| Q3 2025 | 22 | +1 | 50.89M | $3.18B | +2 | −2 |
| Q2 2025 | 19 | -1 | 51.15M | $2.66B | n/a | −1 |
| Q1 2025 | 17 | -1 | 25.07M | $1.07B | n/a | −1 |
| Q4 2024 | 18 | +2 | 25.10M | $766.76M | +2 | n/a |
| Q3 2024 | 15 | +1 | 25.31M | $580.70M | +2 | −1 |
| Q2 2024 | 14 | n/a | 24.13M | $697.01M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford ✦ | 6.09M | n/a | $175.97M | 0.1% | n/c | 1 | SEC ↗ ×4 |
| 2 | Wellington Management ✦ | 3.51M | n/a | $101.33M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 3 | Citadel Advisors ✦ | 3.29M | n/a | $95.04M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 4 | Geode Capital Management ✦ (passive) | 2.79M | n/a | $80.66M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Millennium Management ✦ | 2.14M | n/a | $61.67M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Point72 Asset Management ✦ | 1.82M | n/a | $52.42M | 0.2% | n/c | 1 | SEC ↗ |
| 7 | Norges Bank ✦ (passive) | 1.38M | n/a | $39.96M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 1.38M | n/a | $39.73M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Two Sigma Investments ✦ | 814.52K | n/a | $23.52M | 0.1% | n/c | 1 | SEC ↗ |
| 10 | ARK Investment Management ✦ | 453.59K | n/a | $13.10M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | Adage Capital Partners ✦ | 299.80K | n/a | $8.66M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Gotham Asset Management ✦ | 84.75K | n/a | $2.45M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | PRIMECAP Management ✦ | 66.18K | n/a | $1.91M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Bridgewater Associates ✦ | 20.20K | n/a | $583,405 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 481 holders, 137.05M shares, $11.53B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 116 sh · $19,242
Director · 69 sh · $11,032
Director · 1.10K sh · $192,432
Director · 826 sh · $144,550
Director · 3.30K sh · $578,888
Director · 1.30K sh · $229,236
Director · 971 sh · $172,330
Director · 116 sh · $20,300
Officer · 7.74K sh · $1.38M
Officer · 4.00K sh · $632,193
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology